Sentences with phrase «current contracting prices»

However, at current contracting prices around $ 21 per ton the reserves extend to about 75 years, and the curve is fairly low sloped out far beyond that.

Some coking coal contracts have reportedly been settled at prices more than double current contract price levels.

And appraisers will use these comparable sales to justify the current contract price.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

This purchase part of the contract will specify either an agreed - upon purchase price — which can be higher than the current market value, depending on the length of the rental agreement — or include details of when and how the price will set in the future.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Fair value is a tool used by investors to understand the relationship between the value of futures contracts and the current price of a stock.

These risks include, in no particular order, the following: the trends toward more high - definition, on - demand and anytime, anywhere video will not continue to develop at its current pace or will expire; the possibility that our products will not generate sales that are commensurate with our expectations or that our cost of revenue or operating expenses may exceed our expectations; the mix of products and services sold in various geographies and the effect it has on gross margins; delays or decreases in capital spending in the cable, satellite, telco, broadcast and media industries; customer concentration and consolidation; the impact of general economic conditions on our sales and operations; our ability to develop new and enhanced products in a timely manner and market acceptance of our new or existing products; losses of one or more key customers; risks associated with our international operations; exchange rate fluctuations of the currencies in which we conduct business; risks associated with our CableOS ™ and VOS ™ product solutions; dependence on market acceptance of various types of broadband services, on the adoption of new broadband technologies and on broadband industry trends; inventory management; the lack of timely availability of parts or raw materials necessary to produce our products; the impact of increases in the prices of raw materials and oil; the effect of competition, on both revenue and gross margins; difficulties associated with rapid technological changes in our markets; risks associated with unpredictable sales cycles; our dependence on contract manufacturers and sole or limited source suppliers; and the effect on our business of natural disasters.

There's limited coverage beyond calendar 2012 in part because we believe some commodities will experience cost declines from the current levels and we want to be in a position to benefit from that decline, or because the premiums for future contracts are simply too great compared to what we expect prices will be in the cash market several months from now.

It is a legal contract between 2 parties, a buyer and a seller to agree to pay the difference in the current price of the underlying asset and its contract value.

Iron ore contract price negotiations have also commenced, and price increases of over 50 per cent are possible given the current strength of global steel demand.

In practical terms, arbitrage funds seek spreads between the current price of stocks and their forward value reflected in a futures contract.

However, should slowing global economic growth or recession result in a long - term reduction (three to five years) in energy prices, then U.S. Silica and its peers will face the prospect of their current lucrative contracts expiring and themselves sitting atop literal mountains of frac sand, while demand may have fallen off a cliff.

The potential problem, as with any futures contract, is contango — when the futures price for something is higher than its current price.

Goodman chief Chris Delaney said last year Goodman had «made a mistake» when it signed a private label contract with Coles two years before and he would not be willing to renew the contract at current prices.

«We believe current contracts for the most part are not fit for purpose, with pricing and volume management having significant room for improvements.

Unconscionable conduct (agrees with NFF that they have not provided protection and support reforms «to provide transparency in the supply chain» and recognise that «certain classes of suppliers... are predisposed to suffering from a special disadvantage...»; misuse of market power (legal framework must «level the balance of market power in negotiations...», «ensure transparency in the transmission of market prices» and «not allow for final market risks to be borne by the primary producer» and provide «transparency of contract processes» - specifically, Canegrowers supports effects test and a process giving ACCC greater power to «regulate anti-competitive behaviour and impose penalties», shifting «the decisions framework from the judicial system to a regulatory system» which would make it more accessible to small producers); collective bargaining (notes limits of Sugar Industry Act (Qld); authorisation and notification approval costly and limited and not a viable alternative - peak bodies should be able to «commence and progress collective bargaining with mills on behalf of their members» and current threshold too restrictive)» competitive neutrality (mixed outcomes - perverse outcomes in the case of natural monopolies - suggest remove «application of competitive neutrality provisions to natural monopoly essential services»)

I do have my doubts about this rumour, like all of them, especially when you see the money being talked about as nearly # 50 million, but Manolas is one of the top rated defenders in the world and if the price was a little bit less which it could well be as the contract situation with his current club is said to be the reason for the move, then maybe it could happen.

Most surprisingly, Arsenal are claimed to be setting Bellerin's asking price at just # 35m — a fee that seems staggeringly low in this current market, especially given his contract situation in north London.

The Daily Mirror points out that Ceballos has less than a year to run on his current contract, and also point out that Real Betis may elect to accept a cut - price offer for the player over the possibility of losing him for nothing next summer.

We do not know why the talks with Barca have broken down but with the 29 - year old having a release clause in his current Celta Vigo contract of less than # 13 million it can not be the price.

Mkhitaryan on his way out of BVB 27 - year - old Armenian star Mkhitaryan could be available for a cut - price fee this summer given that he only has one year left on his current Dortmund contract.

Meyer reportedly warranted a # 30m valuation last summer, but having since refused to sign a new contract and with just 12 months remaining on his current deal, it's suggested that he could move on in a cut - price deal this time round.

But I'm not sure that # 50m is a fair price for Sterling, even though he has great promise and an extra year on his current contract.

The 26 year old German international is set to leave the Westfalenstadion and with just a year to run on his current contract it's likely the Gunners could pick up the versatile Dortmund star at a bargain price.

His time at Gladbach is seemingly coming to an end as after refusing to sign a new contract with his current deal expiring in 2018, he is expected to leave in a cut - price move this summer in order for the Bundesliga side to avoid losing him for nothing.

Time for some brutal honesty... this team, as it stands, is in no better position to compete next season than they were 12 months ago, minus the fact that some fans have been easily snowed by the acquisition of Lacazette, the free transfer LB and the release of Sanogo... if you look at the facts carefully you will see a team that still has far more questions than answers... to better show what I mean by this statement I will briefly discuss the current state of affairs on a position - by - position basis... in goal we have 4 potential candidates, but in reality we have only 1 option with any real future and somehow he's the only one we have actively tried to get rid of for years because he and his father were a little too involved on social media and he got caught smoking (funny how people still defend Wiltshire under the same and far worse circumstances)... you would think we would want to keep any goaltender that Juventus had interest in, as they seem to have a pretty good history when it comes to that position... as far as the defenders on our current roster there are only a few individuals whom have the skill and / or youth worthy of our time and / or investment, as such we should get rid of anyone who doesn't meet those simple requirements, which means we should get rid of DeBouchy, Gibbs, Gabriel, Mertz and loan out Chambers to see if last seasons foray with Middlesborough was an anomaly or a prediction of things to come... some fans have lamented wildly about the return of Mertz to the starting lineup due to his FA Cup performance but these sort of pie in the sky meanderings are indicative of what's wrong with this club and it's wishy - washy fan - base... in addition to these moves the club should aggressively pursue the acquisition of dominant and mobile CB to stabilize an all too fragile defensive group that has self - destructed on numerous occasions over the past 5 seasons... moving forward and building on our need to re-establish our once dominant presence throughout the middle of the park we need to target a CDM then do whatever it takes to get that player into the fold without any of the usual nickel and diming we have become famous for (this kind of ruthless haggling has cost us numerous special players and certainly can't help make the player in question feel good about the way their future potential employer feels about them)... in order for us to become dominant again we need to be strong up the middle again from Goalkeeper to CB to DM to ACM to striker, like we did in our most glorious years before and during Wenger's reign... with this in mind, if we want Ozil to be that dominant attacking midfielder we can't keep leaving him exposed to constant ridicule about his lack of defensive prowess and provide him with the proper players in the final third... he was never a good defensive player in Real or with the German National squad and they certainly didn't suffer as a result of his presence on the pitch... as for the rest of the midfield the blame falls squarely in the hands of Wenger and Gazidis, the fact that Ramsey, Ox, Sanchez and even Ozil were allowed to regularly start when none of the aforementioned had more than a year left under contract is criminal for a club of this size and financial might... the fact that we could find money for Walcott and Xhaka, who weren't even guaranteed starters, means that our whole business model needs a complete overhaul... for me it's time to get rid of some serious deadweight, even if it means selling them below what you believe their market value is just to simply right this ship and change the stagnant culture that currently exists... this means saying goodbye to Wiltshire, Elneny, Carzola, Walcott and Ramsey... everyone, minus Elneny, have spent just as much time on the training table as on the field of play, which would be manageable if they weren't so inconsistent from a performance standpoint (excluding Carzola, who is like the recent version of Rosicky — too bad, both will be deeply missed)... in their places we need to bring in some proven performers with no history of injuries... up front, although I do like the possibilities that a player like Lacazette presents, the fact that we had to wait so many years to acquire some true quality at the striker position falls once again squarely at the feet of Wenger... this issue highlights the ultimate scam being perpetrated by this club since the arrival of Kroenke: pretend your a small market club when it comes to making purchases but milk your fans like a big market club when it comes to ticket prices and merchandising... I believe the reason why Wenger hasn't pursued someone of Henry's quality, minus a fairly inexpensive RVP, was that he knew that they would demand players of a similar ilk to be brought on board and that wasn't possible when the business model was that of a «selling» club... does it really make sense that we could only make a cheeky bid for Suarez, or that we couldn't get Higuain over the line when he was being offered up for half the price he eventually went to Juve for, or that we've only paid any interest to strikers who were clearly not going to press their current teams to let them go to Arsenal like Benzema or Cavani... just part of the facade that finally came crashing down when Sanchez finally called their bluff... the fact remains that no one wants to win more than Sanchez, including Wenger, and although I don't agree with everything that he has done off the field, I would much rather have Alexis front and center than a manager who has clearly bought into the Kroenke model in large part due to the fact that his enormous ego suggests that only he could accomplish great things without breaking the bank... unfortunately that isn't possible anymore as the game has changed quite dramatically in the last 15 years, which has left a largely complacent and complicit Wenger on the outside looking in... so don't blame those players who demanded more and were left wanting... don't blame those fans who have tried desperately to raise awareness for several years when cracks began to appear... place the blame at the feet of those who were well aware all along of the potential pitfalls of just such a plan but continued to follow it even when it was no longer a financial necessity, like it ever really was...

Nevertheless, given that his current contract with Everton expires at the end of the season, they could sensibly consider a cut - price deal in January rather than lose him for nothing next summer, provided that the two parties aren't able to reach an agreement to extend his stay.

With four years remaining on his current contract with the Ligue 1 champions, Verratti would have a huge price tag — after the club invested # 8.6 million on the 20 year - old when he was as Pescara [it can potentially rise to # 11.75 million depending on add ons].

Bolasie had 3 years to run on his current contract at Palace and unfortunately, that has seen his price sky rocket.

Sanchez is currently valued at around a price of # 25m and with just six months left on his current Arsenal contract, surely the Gunners would not want to sell their superstar to a direct rival that is Manchester City.

Arsenal value both players in excess of # 75m in the current market but realise their asking prices will plummet if they are allowed to enter the final year of their contracts.

As reported by talkSPORT, Giovinco could be available for a cut - price deal during the transfer window with his current contract at Juventus expiring in the summer.

Academic learning that comes to mind includes more prosaic elements of law, such as contract vs criminal vs administrative law; the developmental history of their own city; recent (50 years) political history of their city; basics of land law; current vs past thinking in urban planning; specific budgetary investigations at both the state and local level; school funding law in their state; essentials of Leadership, EPA impacts on dismantling abandoned structures; economic price theory; or the competitive strengths and weaknesses of their own city or region.

In fact, a flexible contract will give the customer the option to review the contract against current requirements and renegotiate on key deliverables and pricing.

Otherwise, you are looking at current Webstick data pricing at 39.99 which is a little much after 400 for the device on contract.

So, my read is their current contract doesn't care about library pricing.

The no contract pricing will be similar to that of the current Galaxy Tab no contract pricing, and it has more than enough ability to eventually update to Honeycomb.

T - Mobile US today announced that much awaited LG G - Slate will go on sale April 20 for a price of USD 529.99 with a two year contract for current T - Mobile customers after a USD 100 mail - in rebate.

The report presents 145 pages of data and commentary on a broad range of eBook issues, including: spending on eBooks in 2010 and anticipated spending for 2011; use levels of various kinds of eBooks; market penetration by various specific eBook publishers; extent of use of aggregators vs offering by specific publishers; purchasing of individual titles; use of various channels of distribution such as traditional book jobbers and leading retail / internet based booksellers; use of eBooks in course reserves and interlibrary loan; impact of eBooks on print book spending; use of eBooks in integrated search; price increases for eBooks; contract renewal rates for eBooks; use of special eBook platforms for smartphones and tablet computers; spending plans and current use of eBook reader such as Nook, Reader and Kindle; the role played by library consortia in eBooks; Continue reading Primary Research Group releases Library Use of eBooks 2011 Edition →

This cut does not affect the Verizon branded XOOM 3G version, which will remain at its current $ 799.99 retail price point (sans contract).

With the current setup, Tate supposedly offers three types of contracts: a traditional - type offer with an advance; an offer without an advance; and an offer with a $ 4,000 price tag.

Do not sign a contract with a publisher unless they give you an ePUB you can sell in the various suppliers at current industry pricing.

Something else RIM can learn from Apple - Give your current customers, like those of us on a Bold 9700, some kind of deal so that we can pick up the newer models for the «after rebate» price - it isn't the carrier contract that's the problem - As Apple proved, people will stay locked into contracts forever to continue getting the new iPhone.

Again, I was guaranteed that I could get a phone for the subsidized price and continue my current contract even after all of the new plans have taken effect.

The bid represents the current highest price that a buyer is willing to purchase a given options contract.

However, should real rates rise even modestly, it would be much harder to sustain current values, suggesting the sector would be likely to see its multiples (price - to - earnings ratio) contract relative to the broader market.

The Price Limits shall be calculated at the beginning of each calendar quarter, based upon the average closing price of the S&P MidCap 400 futures contract whose expiration date matches that of the current primary E-Mini futures contract, during the month prior to the beginning of the quarter (P) and rounded, as folPrice Limits shall be calculated at the beginning of each calendar quarter, based upon the average closing price of the S&P MidCap 400 futures contract whose expiration date matches that of the current primary E-Mini futures contract, during the month prior to the beginning of the quarter (P) and rounded, as folprice of the S&P MidCap 400 futures contract whose expiration date matches that of the current primary E-Mini futures contract, during the month prior to the beginning of the quarter (P) and rounded, as follows.

5 - Year Treasury Note Futures - Get current 5 - Year Treasury Note futures prices, quotes, charts, 5 - Year Treasury Note futures contract specifications & news.

Contango: If the current price of a crude oil contract is $ 50 per barrel, but the price for delivery in six months is $ 60, that market would be in contango.